| Literature DB >> 15210759 |
Yan-Ming Xu1, Li-Feng Wang, Lin-Tao Jia, Xiu-Chun Qiu, Jing Zhao, Cui-Juan Yu, Rui Zhang, Feng Zhu, Cheng-Ji Wang, Bo-Quan Jin, Si-Yi Chen, An-Gang Yang.
Abstract
Clinical studies have suggested that human epidermal growth factor receptor-2 (HER2) provide a useful target for antitumor therapy. We previously described the generation of a chimeric HER2-targeted immunocasp-3 protein. In this study, we extend the repertoire of chimeric proapoptotic proteins with immunocasp-6, a construct that comprises a HER2-specific single-chain Ab, a single-chain Pseudomonas exotoxin A, and an active caspase-6, which can directly cleave lamin A leading to nucleus damage and inducing programmed cell death. We demonstrate that the secreted immunocasp-6 molecule selectively recognizes and induces apoptosis in HER2-overexpressing tumor cells in vitro, but not in cells with undetectable HER2. The immunocasp-6 gene was next transferred into BALB/c athymic mice bearing human breast SK-BR-3 tumors by i.m. injection of liposome-encapsulated vectors, by intratumor injection of adenoviral vectors, or by i.v. injection of PBMC modified by retroviral infection. Regardless of the method used, expression of immunocasp-6 suppressed tumor growth and prolonged animal survival significantly. Our data show that the chimeric immunocasp-6 molecule can recognize HER2-positive tumor cells, promptly attack their nucleus, and induce their apoptotic death, suggesting the potential of this strategy for the treatment of human cancers that overexpress HER2.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15210759 DOI: 10.4049/jimmunol.173.1.61
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.426